timothy sykes logo

Stock News

Akero Therapeutics’ Stock Rise: What Investors Should Know

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 5/20/2025, 5:03 pm ET 5/20/2025, 5:03 pm ET | 6 min 6 min read
Akero Therapeutics’ Stock Rise: What Investors Should Know Thumbnail

Akero Therapeutics Inc.’s stocks have been trading up by 23.36 percent, driven by promising advancements in their clinical trials.

  • Continued progression in the Phase 2b SYMMETRY study was announced, reinforcing EFX’s capacity to reverse cirrhosis with fewer adverse metabolic effects than expected.

  • Analysts note Akero has enough financial resources to last through 2028, based on current projections, reinforcing investor confidence.

  • Analysis of a 96-week trial period further underscores EFX’s effectiveness, presented at a prominent congress, enhancing the company’s scientific credibility.

  • Investment firms have maintained a buy rating on the back of positive trial results, albeit with slight adjustment in price targets due to evolving market forecasts.

Candlestick Chart

Live Update At 17:02:53 EST: On Tuesday, May 20, 2025 Akero Therapeutics Inc. stock [NASDAQ: AKRO] is trending up by 23.36%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview of Akero Therapeutics

In the fast-paced world of trading, making mistakes is inevitable. It’s crucial for traders to learn from these errors to refine their techniques and strategies. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Keeping this mindset helps traders to remain resilient and adaptable, enabling them to grow and succeed over time.

Akero’s financial results for Q1 2025 are quite telling. The company reported a net loss per share of $0.90, which was better than industry expectations. This smaller loss hints at cost management proficiency, a sign of future stability. Notably, the company’s cash reserves are expected to cover operations till 2028—a comforting thought for stockholders eyeing long-term growth.

During this quarter, Akero focused heavily on research, pouring resources into their promising drug candidate, efruxifermin. The trial results are promising, showing significant decreases in fibrosis without worsening MASH in participants. A significant scientific achievement, these findings were shared with the broader scientific community, boosting Akero’s credibility and value in the eyes of investors.

Examining key financial ratios, Akero firmed up its position as a biotech with a solid balance sheet. Keeping a low debt-to-equity ratio also reduces financial risk, and a high current ratio points to liquidity strength. On a less positive note, recent stock movements show fluctuations. From $38.14 on May 19 to $47.57 on May 25, these swings are largely influenced by trial updates and market sentiment reflected in trading volumes, displaying investor responses to scientific news coupled with financial data.

In broader investment context, stock performance is heavily tied to trial outcomes and Akero’s ability to bring EFX to market successfully. Investors will closely watch how this biology mystic defies the economic odds, following news of positive trial results hinting at future market acceptance.

Key News Influencing the Market

Breakthrough in the Fight Against Liver Diseases

Akero’s announcement of positive findings from the Phase 2b SYMMETRY trial has captured the biotech world’s attention. The drug EFX demonstrated success in reducing fibrosis, a significant milestone in treating chronic liver diseases. This breakthrough is not only a step forward for patients, offering hope against a progressive disease, but it also propels Akero’s standing in the industry, wooing investors and lifting market confidence.

Long-Term Financial Viability

Akero’s financial forecast reassures, suggesting cash reserves to sustain operations into 2028. Such optimism about financial endurance bodes well for investors looking at the longevity of their investment. Cash flow stability resonates in stock valuations and potentially buffers against market ups and downs.

More Breaking News

Scientific Validation and Market Sentiment

As the EFX trials gain recognition at significant academic platforms, such as the EASL Congress 2025, they play a persuasive role in persuasive investor behavior. This credible scientific validation pushes Akero’s stock upwards as the broader market takes note of the company’s potential to tackle significant liver conditions with EFX.

Analyst Insights Amid Price Adjustments

While some analysts have lowered Akero’s price targets to reflect temporal market caution, they still maintain a positive outlook on the stock’s potential. This dual signaling reflects complex market dances—wavering between scientific promise and strategic market forecasting challenges.

Conclusion: Navigating Akero’s Future

In the short-term, Akero’s stock is primarily driven by its clinical trial developments and financial announcements. Both pivotal trial data results and forward-looking cash management offer a promising horizon for traders, particularly when evaluating pharmaceutical innovations that directly translate to market growth.

Akero’s ability to maintain trader confidence through nuanced trial communication and fiscal strategies could be key in cementing its status. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Traders must weigh scientific advancement against broader market conditions to gauge their engagement with Akero effectively. As the company seeks to navigate its drug candidates through regulatory and market hurdles, strategic patience may reward those ready to bet on breakthrough science.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”